
Targeting rare diseases with adenosine modulators
The Vision

The Vision of Palobiofarma is to discover the first marketed drug based on a selective adenosine receptor modulator.
How do we achieve our vision
Palobiofarma focused internal resources on areas where lies the experience of the management team::
- Virtual drug design
- Medicinal Chemistry
- In Vitro Pharmacology of adenosine
- Physico-chemical characterization of the compounds
- Intellectual Property
The remaining activities needed for the full compound characterization and the nomination of a development candidate, such as the pharmacology and toxicology tests, are carried out through partnerships with various companies (CROs), Research Centres and Universities.
Last News
-
Palobiofarma Presents Phase 2 Results for Investigational PBF-999 in Prader-Willi Syndrome
Read more: Palobiofarma Presents Phase 2 Results for Investigational PBF-999 in Prader-Willi SyndromePamplona, Navarra – 23 October 2026 – Palobiofarma announced results from its Phase 2 study of PBF-999, its investigational PDE10A inhibitor for the treatment of Prader-Willi syndrome (PWS), presented at…
-
Palobiofarma announces significant advances in the clinical development of PBF-999 for Prader-Willi Syndrome
Read more: Palobiofarma announces significant advances in the clinical development of PBF-999 for Prader-Willi SyndromePamplona, Spain – May 11st, 2026 – Palobiofarma S.L., a biopharmaceutical company focused on the discovery and development of innovative treatments for orphan diseases, today announced significant progress in the…
